Last quarter (Q1 2024), Tempest Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, Tempest Therapeutics's net income was $-7.90M. See Tempest Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20
Total Revenue	-	-	-	-	$ 0.00
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expense	$ 29.62M	$ 29.16M	$ 34.64M	$ 26.99M	$ 19.30M
Operating Income	$ -29.62M	$ -29.16M	$ -34.64M	$ -26.99M	$ -19.30M
Net Non Operating Interest Income Expense	$ -1.44M	$ 349.00K	$ -1.62M	$ -1.28M	$ 90.00K
Other Income Expense	$ -1.15M	$ 15.00K	$ -549.00K	$ 34.00K	-
Pretax Income	$ -29.91M	$ -29.49M	$ -35.71M	$ -28.30M	$ -19.21M
Tax Provision	-	$ -2.49M	-	-	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -29.91M	$ -29.49M	$ -35.71M	$ -28.30M	$ -19.21M
Basic EPS	$ -1.93	$ -1.91	$ -3.09	$ -7.47	$ -2.89
Diluted EPS	$ -1.93	$ -1.91	$ -3.09	$ -7.47	$ -2.89
Basic Average Shares	$ 64.22M	$ 15.42M	$ 11.55M	$ 3.79M	$ 6.64M
Diluted Average Shares	$ 64.22M	$ 15.42M	$ 11.55M	$ 3.79M	$ 6.64M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 29.62M	$ 29.16M	$ 34.64M	$ 26.99M	$ 19.30M
Net Income From Continuing And Discontinued Operation	$ -29.91M	$ -29.49M	$ -35.71M	$ -28.30M	$ -19.21M
Normalized Income	$ -19.17M	-	-	-	$ -19.21M
Interest Expense	-	-	-	-	$ 0.00
EBIT	$ -28.47M	$ -28.04M	$ -34.09M	-	$ -19.21M
EBITDA	$ -28.08M	$ -27.66M	$ -33.45M	-	$ -18.87M

Currency in USD

Tempest Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing